Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

News headlines Recursion Pharmaceuticals (RXRX) is gaining attention due to positive clinical trial results for its drug REC-4881 and a recent upgrade by JPMorgan. Cathie Wood's ARK Investment also ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

The Space Odyssey series is a science fiction series of two film adaptations from Arthur C. Clarke works. 2001: A Space Odyssey — a film and novel — produced concurrently and released in 1968, and ...